Related Experiment Video

Updated: Dec 29, 2025

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology
09:33

A Methodological Approach to Non-invasive Assessments of Vascular Function and Morphology

Published on: February 7, 2015

16.7K

Soluble ST2 is associated with increased carotid intima-media thickness in patients with type 2 diabetes mellitus: A

Xiaolei Hu1, Hengyan Zhang1, Yuan Song1

  • 1Department of Endocrinology.

Medicine
|February 1, 2020
PubMed

Insights

Soluble suppression of tumorigenicity 2 (sST2) is elevated in patients with type 2 diabetes and abnormal carotid intima-media thickness. Higher sST2 levels correlate with poor glucose control and are a risk factor for diabetic macrovascular complications.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Endocrinology

Background:

  • Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family.
  • Previous research suggests an association between sST2 and diabetes.
  • Cardiovascular risk factors related to sST2 in diabetes remain underexplored.

Purpose of the Study:

  • To investigate the relationship between sST2 and carotid intima-media thickness (CIMT) in patients with type 2 diabetes mellitus (T2DM).
  • To identify sST2 as a potential marker for diabetic macrovascular complications.

Main Methods:

  • 118 T2DM patients were categorized into normal CIMT (NCIMT) and abnormal CIMT (ACIMT) groups.
  • 60 healthy individuals served as normal controls (NC).
  • Carotid intima-media thickness (CIMT) was measured using color Doppler ultrasound; sST2 and metabolic parameters were quantified.

Main Results:

  • Median sST2 levels were significantly higher in the ACIMT group compared to NCIMT and NC groups (P < .01).
  • Elevated sST2 showed strong associations with smoking, fasting plasma glucose (FPG), and HbA1c, and a negative correlation with HDL.
  • sST2 was identified as a risk factor for increased CIMT in T2DM patients.

Conclusions:

  • Increased sST2 levels are linked to indicators of glucose and lipid metabolism in T2DM.
  • sST2 is a significant risk factor for increased CIMT, suggesting its role in diabetic macrovascular complications.
  • sST2 may serve as a novel biomarker for assessing the progression of diabetic macrovascular complications.

More Related Videos

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome06:04

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

1.4K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.3K

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
800
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
388
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.6K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
692
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
279